Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/165 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME14713399
PMID: | 14713399
LR: | 20051116
CED: | 20040109
DCO: | 20040426
Autoren: | Strand V; Kelman A
Titel: | Outcome measures in osteoarthritis: randomized controlled trials.
Quelle: | Current rheumatology reports; VOL: 6 (1); p. 20-30 /200402/
PM: | Print
SU: | IM
Sprache: | English
CY: | United States
JID: | 100888970
ISSN: | 1523-3774
Institution: | Division of Immunology and Rheumatology, Stanford University, 306 Ramona Road, Portola Valley, CA 94028, USA. vstrand@aol.com
DT: | Journal Article; Review
RN: | 89
Schlagwörter
CT: | ACUPUNCTURE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/therapeutic use; CYCLOOXYGENASE INHIBITORS/*therapeutic use; DISABILITY EVALUATION; GLUCOSAMINE/therapeutic use; HUMANS; LOW BACK PAIN/etiology; LOW BACK PAIN/physiopathology; OSTEOARTHRITIS/complications; OSTEOARTHRITIS/drug therapy; OSTEOARTHRITIS/physiopathology; OSTEOARTHRITIS/*therapy; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; QUALITY OF HEALTH CARE/*; RANDOMIZED CONTROLLED TRIALS
CTG: | AKUPUNKTUR; ANTIPHLOGISTIKA, NICHTSTEROIDALE/therapeutische Anwendung; CYCLOOXYGENASEINHIBITOREN/*therapeutische Anwendung; INVALIDITÄTSBEURTEILUNG; GLUCOSAMIN/therapeutische Anwendung; MENSCH; KREUZSCHMERZEN/Ätiologie; KREUZSCHMERZEN/Pathophysiologie; OSTEOARTHROSE/Komplikationen; OSTEOARTHROSE/Arzneimitteltherapie; OSTEOARTHROSE/Pathophysiologie; OSTEOARTHROSE/*Therapie; BEHANDLUNGSERGEBNISBEURTEILUNG (GESUNDHEITSWESEN); SCHMERZMESSUNG; QUALITÄT DES GESUNDHEITSWESENS/*; RANDOMISIERTE KONTROLLIERTE STUDIEN
TE: | Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Glucosamine/3416-24-8
CR: | 3416-24-8
AB: | Accepted outcome measures in randomized controlled trials (RCTs) in osteoarthritis (OA) include patient-reported assessments of physical function and health-related quality of life (HRQOL). Available data can inform treatment decisions when statistically significant changes are viewed in terms of clinically important improvements. Patient-reported outcomes validated in OA include global assessments of pain, disease activity, and disease-specific and generic measures of physical function and HRQOL. Definitions of minimum clinically important differences (MCID) have been derived from RCTs with physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 selective agents. Definitions of MCID should serve only as guidelines based on mean changes in a treatment group, and do not necessarily reflect clinically meaningful improvements for an individual patient. They help to interpret data across treatments and patient populations. Definitions of MCID may differ for the type of intervention assessed; additional methodologic issues must be addressed when evaluating nonpharmacologic treatments. Based on RCTs in OA evaluating physical therapy, cyclooxygenase-2 agents, and NSAIDs, the Western Ontario and McMaster Osteoarthritis Index is valid, reliable, sensitive to change, and correlates closely with the generic Medical Outcomes Survey Short-Form 36 measure of HRQOL. When evaluating RCT data, understanding derivation and MCID values of outcome measures facilitates informed therapeutic decisions regarding therapeutic interventions.

» Volltext »
» Fenster schließen »